Eisai, Purdue Pharma deal

Eisai’s Eisai Inc. subsidiary and Purdue partnered to develop and commercialize Eisai’s lemborexant ( E2006) to treat insomnia, for which it has completed Phase II testing. The deal may be expanded to include other indications. The companies will form a joint steering committee to manage worldwide development and commercialization and will share the costs of clinical trials of the dual orexin receptor antagonist. ...